Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

Susan Bernstein  |  Issue: April 2016  |  April 15, 2016

How Much Savings?

It’s hard to predict the financial savings of biosimilars until they come to market. By looking at past biologic sales, potential discounting due to increased competition, European biosimilar prices and increasing penetration of the drug market over the next decade, cost savings may top $44 billion over the next decade, and biosimilar price discounts may be as much as 35% lower, according to a 2014 study released by the RAND Corp. 

Patients like Carolyn Amisano, who’s had RA for 42 years, say lower prices will make drugs accessible to more people who need them. “The price will make a real difference in whether you’d be able to take that medicine. If they can come out with something more affordable, it would be great for many people, and saving a lot of families,” said Ms. Amisano, who has used two biologics in the past. “It’s a shame if you have to let drug costs influence your health. As long as I know it will work, and if it’s going to do the same thing, then it would be tremendous.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although patients like Ms. Amisano are used to generic drugs, biosimilars won’t be as simple a switch, said Martin Zagari, MD, vice president of global health economics at Amgen, the biopharmaceutical company based in Thousand Oaks, Calif. Communication about biosimilars will help allay fears and confusion.

“We believe even more expertise will be required from such groups as the ACR. We should expect that most people are predicting that this notion of precision medicine and personalized medicine actually increases the role of deep expertise and patient-centeredness,” he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Room for Innovation

Savings generated by biosimilars will also open space in research and development budgets for future breakthrough products, said Dr. Zagari. “The medicines that are now seen as the most expensive are also going to be the ones that are creating new headroom for treatment. When these molecules are able to be provided in biosimilar form, they will have an effect on the system as profound as generic drugs have had to date.”

Focus on the improved, long-term health outcomes that more affordable biologic drugs can provide and the savings they will offer, he said.

“Predictability of innovation is actually becoming more and more something that we can count on as a society. How can we afford new medicines? In the 1980s and 1990s, only about one-third of medicines were generic. Now, it’s almost 90% of prescriptions. This is how we get [healthcare costs] under control,” he said.

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesLegislation & Advocacy Tagged with:BiologicsBiosimilarscost savingdebatedrugFDApatient careRheumatic DiseaserheumatologySafetyTreatment

Related Articles

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences